NEW YORK (GenomeWeb News) – Shares in Accelr8 plummeted nearly 30 percent today following news that Becton Dickinson has declined an option to license the company's rapid bacterial diagnostic system.

BD advised the company that it would decline an exclusive license option to the technology associated with an 18-month testing agreement it inked with Accelr8 in April 2008.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.